left-arrow right-arrow pinterest facebook google_plus linkedin

SWOG S1706

Status:

Recruiting | Phase II

Official Title:

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Study Purpose:

To determine if adding the drug olaparib to the usual radiation therapy for inflammatory breast cancer will decrease the risk of cancer returning.

Interventions:

  • Olaparib (Lynparza®)
  • Radiation Therapy
  • Lab Biomarker Analysis
  • ARM I: Olaparib 25mg BID + Standard Radiation Therapy
  • ARM II: Radiation Therapy Alone

Patients will be followed every 3 months from start of study for the first 3 years, and then every 6 months until 8 years from start of study.

Key Participation Requirements: 

Gender: 

Male or female

Age:

19 years and older

Diagnosis:

Breast cancer patients who have had surgery and whose cancer is diagnosed as inflammatory.

Marker Status:

All ER/PR/Her2 statuses are accepted

Eligibility:

Must have completed chemotherapy before mastectomy, as well as the mastectomy, itself.

They may or may not have had chemotherapy after surgery.

Must be registered to the study at least 3 weeks, but no more than 12 weeks after mastectomy.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

SWOG S1706

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!